Home
- BeiGene Facts
- Founded 2010
- Listings NASDAQ: BGNE HKEX: 06160
- Internally Developed
Clinical Candidates 6 - Marketed Products
in China 3 - Global Team 1700+
BeiGene News
- February 19, 2019BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma
BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma
- February 13, 2019BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong
BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong
- February 7, 2019BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day
BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day
- January 14, 2019BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
- January 14, 2019BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
- January 3, 2019BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2010
- BeiGene starts as a research and development company
2012
- Began work on both a PD-1 antibody and a BTK inhibitor
2014
- Started clinical trials of pamiparib and zanubrutinib
2016
- Went public on the Nasdaq, with $182 million initial public offering
2018
- 50+ ongoing or planned clinical trials
Partnering
Partnerships that ExtendAround the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships